Healthcare
Study Finds Prasugrel May Offer Better Outcomes Than Ticagrelor for Diabetic Patients With Stents
New research presented at the American Heart Association's Scientific Sessions 2025 suggests prasugrel may be more effective than ticagrelor at preventing heart attacks, strokes, bleeding complications and death in diabetic patients who received coronary stents, challenging current interchangeable use of these antiplatelet medications.
Minnesota Patient Achieves Chronic Pain Recovery Through Non-Surgical Treatment Approach
A Woodbury resident overcame five years of chronic neck pain and mobility issues through ALIGN Integrated Health's comprehensive non-surgical treatment program, demonstrating an effective alternative to invasive procedures.
Lantern Pharma CEO Details AI Platform's Role in Accelerating Cancer Drug Development
Lantern Pharma is using artificial intelligence to significantly reduce the time and cost of oncology drug development while expanding treatment options for cancer patients.
GeoVax Emphasizes Vaccine Innovation and Trust Building on World Immunization Day
GeoVax Labs is advancing next-generation multi-antigen vaccines and U.S. manufacturing capabilities to address declining public confidence in newer vaccines while protecting vulnerable populations.
American Heart Association Issues New Framework for Responsible AI Implementation in Healthcare
The American Heart Association has released new guidance addressing the critical gaps in AI evaluation and monitoring in healthcare, providing a practical framework to ensure AI tools deliver clinical benefits while protecting patients from potential harms.
Special Education Resource Offers Tailored Homeschool Programs for Children with Autism
Special Education Resource provides structured homeschooling solutions for children with autism, addressing the growing trend of families seeking personalized education that accommodates sensory needs and learning styles.
Family-Based Program Reduces Blood Pressure by 10 mm Hg in Rural Chinese Communities
A family-focused health intervention in rural China achieved significant blood pressure reductions through community support and lifestyle changes, offering a scalable model for cardiovascular disease prevention in resource-limited areas.
Financial Incentives Double Blood Pressure Medication Use But Fail to Improve Health Outcomes
A new study reveals that while daily cash rewards doubled medication adherence among high blood pressure patients, the improved compliance did not translate to better blood pressure control, highlighting the complexity of long-term behavior change.
Food Delivery and Dietary Counseling Program Shows Promise in Reducing Blood Pressure for Black Adults in Food Deserts
A study presented at the American Heart Association's Scientific Sessions 2025 demonstrates that providing home-delivered groceries and dietary counseling significantly improved blood pressure and cholesterol levels in Black adults living in food deserts, though benefits disappeared when support ended, highlighting the need for sustained interventions to address food access barriers.
American Heart Association Launches National Initiative to Combat Rising Heart Valve Disease Deaths
The American Heart Association has launched a comprehensive Heart Valve Initiative to address the growing mortality from heart valve disease, which affects over 28 million people worldwide and contributes to more than 60,000 annual U.S. deaths through improved diagnosis, treatment protocols, and public awareness.
Sgt. Bo Named Winner of 15th Annual American Humane Hero Dog Awards
Sgt. Bo, a therapy dog who provided crucial emotional support to Nashville students after the Covenant School shooting, has been honored as the 2025 American Humane Hero Dog, highlighting the vital role animals play in community healing and crisis response.
Tailored Vitamin D Doses Reduce Heart Attack Risk by 52% in Heart Disease Patients
Adults with heart disease who received personalized vitamin D supplementation to achieve optimal blood levels experienced more than half the risk of heart attack compared to those without vitamin D monitoring, according to preliminary research presented at the American Heart Association's Scientific Sessions 2025.
Daily Coffee Consumption Linked to Reduced AFib Recurrence in New Clinical Trial
A new clinical trial reveals that adults with atrial fibrillation who drank one cup of coffee daily were 39% less likely to experience recurrent AFib episodes, challenging conventional medical advice about caffeine avoidance for heart rhythm patients.
Earlier Blood Transfusions May Reduce Heart Failure Risk in Cardiac Patients After Surgery
A new study suggests that transfusing blood earlier in patients with heart disease undergoing major surgery may significantly reduce the risk of heart failure and irregular heartbeat without increasing severe complication rates.
Catheter Ablation May Eliminate Need for Blood Thinners in Some AFib Patients, Study Finds
New research suggests successful catheter ablation for atrial fibrillation reduces stroke risk enough that many patients can safely discontinue potent blood thinners in favor of aspirin, potentially reducing bleeding complications while maintaining stroke protection.
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Fifth Annual Sickle Cell Caregiver Summit Focuses on Mental Wellness and Advocacy
The upcoming virtual Sickle Cell Caregiver Summit brings global attention to the critical role of caregivers in managing sickle cell disease while addressing mental health challenges and building advocacy skills.
Milevista Partners with Operation Smile to Raise $6.7 Million for Cleft Care by 2027
Milevista's partnership with Operation Smile combines experiential marketing expertise with global medical nonprofit capabilities to fund life-changing surgeries and comprehensive care for children with cleft conditions.
Voyageur Pharmaceuticals Appoints Financial Veteran Virginia Alling to Board, Accelerating U.S. Market Strategy
Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling to its board of directors, strengthening its financial expertise to drive U.S. market expansion and capital market access for its pharmaceutical-grade barium and iodine contrast media products.
Immune Cell Surface Sugar Shedding Identified as Key Factor in Psoriasis Progression
New research reveals immune cells shed surface sugars before entering inflamed skin in psoriasis patients, potentially opening new treatment pathways for the chronic autoimmune condition.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.
Olympus Announces Major Restructuring Strategy to Transform Endoscopy Care Through AI and Robotics
Olympus Corporation unveiled a comprehensive corporate strategy focused on advancing AI-powered endoscopy and robotics while implementing significant workforce reductions and organizational changes to drive innovation in medical technology.
Knecht Orthodontics Expands Access to Advanced Dental Care in Mont Belvieu
Knecht Orthodontics in Mont Belvieu is enhancing local healthcare access by offering comprehensive orthodontic treatments including traditional braces and Invisalign, supported by advanced technology and flexible payment options.
Strawberry Fields REIT Reports Record Q3 2025 Performance with Strategic Healthcare Facility Acquisitions
Strawberry Fields REIT achieved strong third-quarter 2025 results including record rental income and strategic expansion through $68.55 million in healthcare facility acquisitions, demonstrating robust growth in the healthcare real estate sector.
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.